Santosh Kumar Jha
Rapti Academy of Health Sciences, Dang, Nepal
*Address for Corresponding Author
Assistant Professor
Rapti Academy of Health Sciences, Dang, Ghorahi, 22400, Nepal
Abstract
This study systematically reviews and analyzes the impact of vitamin D therapy in chronic kidney disease (CKD) patients. The objective of the research is to assess the effectiveness of vitamin D supplementation, including dietary supplements and active analogs, in improving clinical outcomes and surrogate biomarkers such as parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and arterial stiffness in CKD patients. The materials and methods involved conducting a meta-analysis of randomized controlled trials (RCTs) published between January 2020 and April 2023. A total of 15 RCTs met the inclusion criteria, focusing on adult CKD patients (stages 3-5) with interventions including dietary vitamin D supplements or active analogs. The statistical analysis utilized random-effects models for dichotomous and continuous outcomes. Results indicated that while vitamin D supplementation showed improvements in surrogate biomarkers, such as reduced PTH and FGF23 levels, it did not significantly impact hard clinical outcomes like mortality or cardiovascular events. The conclusion emphasizes the potential of vitamin D therapy in improving biomarkers related to CKD but suggests the need for large-scale, long-term trials to confirm its clinical benefits.
Keywords: Chronic kidney disease, vitamin d therapy, randomized controlled trials, mortality, surrogate biomarkers, parathyroid hormone, fibroblast
